Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer - Concepedia

Concepedia

Publication | Open Access

Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

DOI Full Paper Access

212

Citations

18

References

2008

Year

Celestia S. Higano, John M. Corman, David C. Smith, Arthur S. Centeno, Christopher P. Steidle, Marc Gittleman, Jonathan W. Simons, Natalie Sacks, Junko Aimi, Eric J. Small

Abstract

This immunotherapy was well tolerated. Immunogenicity and overall survival varied by dose. Two phase 3 trials in patients with metastatic HRPC are underway.

References

	Year	Citations

Page 1